Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,802.00
Bid: 1,808.00
Ask: 1,814.00
Change: 48.00 (2.74%)
Spread: 6.00 (0.332%)
Open: 1,740.00
High: 1,830.00
Low: 1,740.00
Prev. Close: 1,754.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Appointment

29 Jun 2020 07:00

RNS Number : 2951R
Genus PLC
29 June 2020
 

For Immediate Release 29 June 2020 

Genus plc('Genus', or the 'Company')

Appointment of Non-Executive Director and Chairman Designate

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Iain Ferguson has been appointed by the Board as an Independent Non-Executive Director with effect from 1 July 2020, and will succeed Bob Lawson as Chairman of the Company at the conclusion of the Company's next Annual General Meeting ('AGM') in November 2020. Iain has been appointed as a member of the Nominations and Remuneration Committees, and will become Chair of the Nominations Committee upon Bob Lawson's retirement.

Iain brings extensive Board and governance experience relevant to Genus, as well as strong commercial, science and agribusiness expertise across a range of industries, with a particular focus on consumer goods and food. Iain is currently Chairman of Crest Nicholson Holdings plc and a Non-Executive Director of Personal Assets Trust plc, and was previously the Senior Independent Director of the animal genetics company Sygen International plc until 2006, when it was acquired by Genus. He was Chairman of Stobart Group Ltd and Senior Independent Director of Balfour Beatty plc until 2019 and Chairman of Berendsen plc until 2017.

Iain joined Unilever plc, one of the world's largest Consumer Goods Groups, in 1977 and built his career in a variety of roles including General Manager, Unilever AgriBusiness, Executive Chair, Unilever Plantations and Plant Sciences Group, and Senior Vice President, Corporate Development, before joining Tate & Lyle plc as Chief Executive in 2003.

Iain's appointment follows an extensive search process using an external search agency.

Commenting on the appointment, Lesley Knox, the Company's Senior Independent Director who led the planned succession process, said, "For over a decade, Bob Lawson has led the successful transformation of Genus to become a world leader in the provision of elite bovine and porcine genetics and related services. I am delighted that Iain has agreed to join Genus and transition into the Chairman role. I believe that Iain brings the right mix of Board experience, international exposure and business skills to maintain the continued growth of the Company and its seamless execution on strategy. The transition period prior to the AGM will enable Iain to gain a strong understanding of the Company's business before becoming the Chairman in November."

Iain Ferguson added, "I am delighted to have been appointed as a Director and Chairman-designate of Genus. I look forward to working with the Chairman, Bob Lawson, the Board, the executive committee and the rest of the Genus team on the opportunities ahead for this great Company."

Bob Lawson, Chairman of Genus, commented "Genus is an outstanding company and one that I have been extremely proud to have worked for. I look forward to assisting Iain in understanding the Company's operations and wish him every success as he sets out to lead Genus through the next stage of our growth."

 

 

Genus

Tel: +44(0)1256 345970

Bob Lawson, Chairman

Stephen Wilson, Chief Executive

Buchanan

Tel: +44(0)207 466 5000

Charles Ryland /Chris Lane

This announcement is available on the Genus website www.genusplc.com

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

Details of any payments to be made to Iain Ferguson will be disclosed in full in the Company's 2020 Directors' Remuneration Report. Any such terms will be consistent with the Company's approved Directors' Remuneration Policy.

 

This announcement is made in accordance with Listing Rule 9.6.11R. There are no matters to be disclosed in connection with Listing Rule 9.6.13R (2) - (6). The person responsible for making this announcement on behalf of the Group is Dan Hartley (General Counsel and Company Secretary).

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEANKPAEKEEFA
Date   Source Headline
2nd Jun 20177:00 amRNSTotal Voting Rights
1st Jun 20177:05 amRNSUpdate Regarding The Milk Pension Fund
2nd May 20173:00 pmRNSTotal Voting Rights
12th Apr 20174:48 pmRNSDirector/PDMR Shareholding
3rd Apr 20172:00 pmRNSTotal Voting Rights
3rd Apr 20177:00 amRNSSUCCESSFUL LEGAL OUTCOME FOR GENUS
15th Mar 20175:15 pmRNSDirector/PDMR Shareholding
15th Mar 201712:00 pmRNSDirector Declaration
1st Mar 201710:09 amRNSDirector/PDMR Shareholding
23rd Feb 20174:20 pmRNSCorrection of Record Date
23rd Feb 20177:00 amRNSInterim Results
23rd Feb 20177:00 amRNSAcquisition and strategic partnership
7th Feb 20174:00 pmRNSHolding(s) in Company
1st Feb 20172:00 pmRNSBlock listing Interim Review
13th Dec 20163:39 pmRNSDirector/PDMR Shareholding
1st Dec 20162:00 pmRNSTotal Voting Rights
17th Nov 20162:01 pmRNSResult of AGM
17th Nov 20167:00 amRNSAGM - Trading Update
1st Nov 20164:00 pmRNSTotal Voting Rights
31st Oct 20163:47 pmRNSAnnual Report and Annual General Meeting
26th Oct 20164:00 pmRNSHolding(s) in Company
11th Oct 20164:08 pmRNSDirector/PDMR Shareholding
3rd Oct 20166:09 pmRNSBlock Listing and Additional Listing
3rd Oct 20165:57 pmRNSTotal Voting Rights
29th Sep 20165:00 pmRNSDirector/PDMR Shareholding
15th Sep 20165:00 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
8th Sep 20167:00 amRNSPreliminary Results
7th Sep 20167:00 amRNSNON-EXECUTIVE DIRECTOR RETIREMENT
1st Sep 20164:17 pmRNSTotal Voting Rights
15th Aug 20167:00 amRNSFINAL JURY DECISIONS IN US LITIGATION
12th Aug 20167:00 amRNSFURTHER DECISIONS IN US LITIGATION
11th Aug 20167:00 amRNSFIRST DECISIONS IN US ANTI-TRUST LITIGATION
1st Aug 20169:20 amRNSBlock listing Interim Review
1st Aug 20169:09 amRNSTotal Voting Rights
27th Jul 20167:00 amRNSSigns exclusive licence for tech. to combat BRD
15th Jul 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
1st Jul 20163:10 pmRNSTotal Voting Rights
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
1st Jun 20162:00 pmRNSTotal Voting Rights
18th May 20167:00 amRNSExclusive Licence for Leading Gene Editing Tech
3rd May 20162:29 pmRNSTotal Voting Rights
13th Apr 20163:13 pmRNSDirector/PDMR Shareholding
1st Apr 20163:31 pmRNSDirector/PDMR Shareholding
9th Mar 20165:03 pmRNSDirector/PDMR Shareholding
4th Mar 20169:30 amRNSBOARD APPOINTMENT
3rd Mar 20162:00 pmRNSDirector/PDMR Shareholding
1st Mar 20165:17 pmRNSDirector/PDMR Shareholding
23rd Feb 20167:00 amRNSINTERIM RESULTS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.